Mereo BioPharma Group PLC (MREO)
Stock Price:
$2.36 USD
-0.11 (-4.45%)
Updated Oct 28, 2020 12:50 PM EDT - Market open
Key Info
| Market Cap |
159.29M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-34.84M |
| Shares Out |
67.50M |
| EPS (ttm) |
-2.05 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 28, 2020 |
| Last Price |
$2.36 |
| Previous Close |
$2.47 |
| Change ($) |
-0.11 |
| Change (%) |
-4.45% |
| Day's Open |
2.36 |
| Day's Range |
2.26 - 2.47 |
| Day's Volume |
49,661 |
| 52-Week Range |
0.69 - 4.25 |
More Stats
| Market Cap |
159.29M |
| Enterprise Value |
180.43M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
67.50M |
| Float |
58.80M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-2.05 |
| FCF / Share |
-3.39 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
946,330 |
| Short Ratio |
6.26 |
| Short % of Float |
1.61% |
| Beta |
1.03 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
5.52 |
| Revenue |
n/a |
| Operating Income |
-52.00M |
| Net Income |
-34.84M |
| Free Cash Flow |
-60.46M |
| Net Cash |
-21.14M |
| Net Cash / Share |
-0.32 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-20.81% |
| ROE |
-344.02% |
| ROIC |
-174.60% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
8.00
Current: $2.36
High
8.00
Target: 8.00
*Average 12-month USD price target from 1 stock analysts.
Financial Performance
Financial numbers in millions GBP.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | - | - | - | - |
| Operating Income | -39.52 | -34.48 | -45.30 | -36.18 |
| Net Income | -34.84 | -32.03 | -38.80 | -28.39 |
| Shares Outstanding | 71.24 | 86.99 | 86.99 | 86.99 |
| Earnings Per Share | -1.56 | -1.80 | -2.24 | -2.52 |
| Operating Cash Flow | -45.93 | -23.14 | -32.15 | -29.66 |
| Capital Expenditures | -0.02 | -0.03 | -0.02 | - |
| Free Cash Flow | -45.95 | -23.17 | -32.17 | -29.66 |
| Cash & Equivalents | 16.35 | 27.54 | 52.54 | 53.58 |
| Total Debt | 32.42 | 21.49 | 20.75 | - |
| Net Cash / Debt | -16.07 | 6.06 | 31.79 | 53.58 |
| Assets | 86.45 | 67.28 | 96.34 | 86.76 |
| Liabilities | 46.19 | 34.51 | 33.85 | 7.51 |
| Book Value | 40.26 | 32.77 | 62.48 | 79.26 |
Numbers in millions GBP, except per-share numbers.
Company Details
| Full Name |
Mereo BioPharma Group PLC |
| Country |
United Kingdom |
| Employees |
50 |
| CEO |
Denise Vera Scots-Knight |
Stock Information
| Ticker Symbol |
MREO |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: MREO |
Description
Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company also develops Navicixizumab (OMP-305B83) that is in Phase 1a clinical trial for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfect; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.